Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H, Hong SH, Kim JY, Kim IC, Park YW, Lee SJ, Song SW, Kim JJ, Park G, Kim TM, Kim YH, Park JB, Chung J, Kim IH. Kim H, et al. Among authors: kim jy, kim yh, kim ih, kim jj, kim tm, kim ic. Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21. Exp Mol Med. 2017. PMID: 28336956 Free PMC article.
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, Lee KH, Ahn JS, Kim TY, Kim GM, Park IH, Kim SB, Kim SH, Han HS, Im YH, Ahn JH, Kim JY, Kang J, Im SA. Park YH, et al. Among authors: kim sb, kim jy, kim ty, kim sh, kim gm, kim jh. Int J Cancer. 2018 Dec 15;143(12):3240-3247. doi: 10.1002/ijc.31651. Epub 2018 Nov 7. Int J Cancer. 2018. PMID: 29978467 Clinical Trial.
12,727 results
You have reached the last available page of results. Please see the User Guide for more information.